Abstract
The treatment of chronic arthritic diseases has undergone some dramatic changes over the past few years. In particular, a new class of drugs called the tumor necrosis factor-α antagonists has transformed the management of rheumatoid arthritis, and decision makers are now considering their use in psoriatic arthritis and ankylosing spondylitis. Whilst short-term clinical trials suggest that tumor necrosis factor-α antagonists improve physical function and pain linked to disease activity; this class of drug has generated controversy owing to its substantial cost. Pharmacoeconomic studies conclude that tumor necrosis factor-α antagonists result in significant increases in health-related quality of life; however, the cost-effectiveness of this class of drug remains uncertain, particularly in the treatment of psoriatic arthritis and ankylosing spondylitis. This paper reviews pharmacoeconomic analyses examining the cost-effectiveness of tumor necrosis factor-α inhibitors in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Original language | English |
---|---|
Pages (from-to) | 155-169 |
Number of pages | 15 |
Journal | Expert Review of Pharmacoeconomics & Outcomes Research |
Volume | 7 |
Issue number | 2 |
DOIs | |
Publication status | Published - Apr 2007 |
Keywords
- Adalimumab
- Ankylosing spondylitis
- Biological response modifier
- Cost-effectiveness analysis
- Etanercept
- Infliximab
- Psociatic arthritis
- Rheumatoid arthritis